AYSE MINDIKOGLU to Biomarkers
This is a "connection" page, showing publications AYSE MINDIKOGLU has written about Biomarkers.
Connection Strength
0.517
-
Intermittent fasting from dawn to sunset for four consecutive weeks induces anticancer serum proteome response and improves metabolic syndrome. Sci Rep. 2020 10 27; 10(1):18341.
Score: 0.094
-
Cystatin C Is a Gender-Neutral Glomerular Filtration Rate Biomarker in Patients with Cirrhosis. Dig Dis Sci. 2018 03; 63(3):665-675.
Score: 0.078
-
A pilot study to evaluate renal hemodynamics in cirrhosis by simultaneous glomerular filtration rate, renal plasma flow, renal resistive indices and biomarkers measurements. Am J Nephrol. 2014; 39(6):543-52.
Score: 0.060
-
Current concepts in the diagnosis and classification of renal dysfunction in cirrhosis. Am J Nephrol. 2013; 38(4):345-54.
Score: 0.057
-
Performance of chronic kidney disease epidemiology collaboration creatinine-cystatin C equation for estimating kidney function in cirrhosis. Hepatology. 2014 Apr; 59(4):1532-42.
Score: 0.057
-
Gender disparity in liver transplant waiting-list mortality: the importance of kidney function. Liver Transpl. 2010 Oct; 16(10):1147-57.
Score: 0.047
-
HELLP syndrome complicated bile duct injury and subsequent left hepatic lobe atrophy. Dig Dis Sci. 2006 Jul; 51(7):1206-12.
Score: 0.035
-
Evaluation of novel candidate filtration markers from a global metabolomic discovery for glomerular filtration rate estimation. Kidney Int. 2024 Mar; 105(3):582-592.
Score: 0.029
-
Modulation of endothelial cell inflammatory integrins and stress markers with rh-factor VIIa in patients with advanced chronic hepatitis C. J Viral Hepat. 2003 Jul; 10(4):310-7.
Score: 0.028
-
Renal dysfunction in cirrhosis. Curr Opin Gastroenterol. 2015 May; 31(3):215-23.
Score: 0.016
-
Recombinant human factor VIIa-induced alterations in tissue factor and thrombomodulin in patients with advanced liver cirrhosis. J Gastroenterol Hepatol. 2005 Jun; 20(6):882-9.
Score: 0.008
-
Platelet sparing effect of COX II inhibition used with pegylated interferon alfa-2a for the treatment of chronic hepatitis C: a short term pilot study. Cytokine. 2004 Sep 21; 27(6):159-65.
Score: 0.008